Author
Year
Reference
n
Technique
Total dose (Gy)
Dose per fraction (Gy)
Visual outcome
Tumor outcome
Re-progression (%)
Radiation-induced toxicities
Improved (%)
Stable (%)
Worse (%)
Control (%)
Progression (%)
Acute (%)
Late (%)
Smith et al.
1981
[12]
5
2DRT
53
2
80
20
0
100
0
0
None
Dry eye (20 %)
Cataract (20 %)
Kupersmith et al.
1987
[13]
4
2DRT
55
1.8
75
25
0
100
0
0
NR
NR
Sarkies et al.
1987
[14]
4
2DRT
40
3.3
0
50
50
100
0
0
NR
NR
Kennerdell et al.
1988
[7]
6
2DRT
55
1.8
100
0
0
100
0
0
None
None
Becker et al.a
2002
[4]
42
FSRT
54
1.8
31
67
2
100
0
0
Erythema (25 %)
None
Alopecia (100 %)
Turbin et al.
2002
[15]
18
3DCRT
40–55
1.4–1.8
44
NR
NR
100
0
0
NR
NR
Andrews t al.
2002
[16]
33
FSRT
51
1.8
42
50
8
100
0
0
NR
Optic neuritis (3 %)
Pitz et al.a
2002
[17]
16
FSRT
54
1.9
40
60
0
100
0
0
Erythema (30 %)
Pituitary disorder (7 %)
Alopecia (68 %)
Liu et al.
2002
[18]
5
FSRT
45–54
1.8
80
20
0
100
0
0
None
None
Saeed et al.
2003
[19]
6
FSRT
14
14
83
0
17
100
0
0
NR
NR
Narayan et al.
2003
[20]
14
3DCRT
45–54
1.8–2.0
36
50
14
100
0
0
Eye pain (7 %)
Dry eye (7 %)
Retinopathy (7 %)
Baumert et al.
2004
[21]
23
FSRT
43–45
1.8–2.0
70
22
8
100
0
0
Eye pain (4 %)
Retinopathy (7 %)
Richards et al.
2005
[22]
4
FSRT
50–54
1.7
100
0
0
100
0
0
NR
NR
Landert et al.
2005
[23]
7
FSRT
52–59
1.7–1.8
86
0
14
100
0
0
NR
NR
Sitathanee et al.
2006
[24]
12
FSRT
45
1.8
33
58
9
100
0
0
None
None
Litré et al.
2007
[25]
8
FSRT
50
1.8
100
0
0
100
0
0
None
Vitreous hemorrhage (13 %)
Arvold et al.
2009
[10]
22
FSRT
50–58
1.8
63
32
5
100
0
1
None
Retinopathy (14 %)
Milker-Zabel et al.
2009
[26]
32
FSRT
50
1.8
38
59
3
100
0
0
NR
Optic neuritis (3 %)
Smee et al.
2009
[27]
12
3DCRT
50–54
1.8–2.0
92
0
8
100
0
0
None
None
Saeed et al.
2010
[6]
34
3DCRT/FSRT
45–54
1.8
41
50
9
100
0
0
Erythema (47 %)
Dry eye (15 %)
Alopecia (10 %)
Cataract (9 %)
Retinopathy (9 %)
Lesser et al.
2010
[6]
11
3DCRT
54
1.8
91
9
100
0
0
NR
NR
Liu et al.
2010
[28]
30
SRS
10–17
NR
36
44
20
100
0
0
None
None
Kurt et al.
2010
[29]
2
SRS
10–17
3.5–6.5
100
0
0
100
0
0
None
None
Metellus et al.
2011
[30]
9
3DCRT
58
1.8
78
22
0
100
0
0
NR
NR
Abouaf et al.
2011
[3]
10
2DRT/
3DCRT/
54
1.8–2.0
60
10
30
100
0
0
Conjunctivitis (10 %)
Dry eye (20 %)
FSRT/IMRT
Alopecia (10 %)
Cataract (40 %)
Retinopathy (20 %)
Adeberg et al.